CERES BRAIN Therapeutics is dedicated to treat cerebral diseases with a first focus on rescuing suffering neurons with creatine through an innovative "creatine-to-brain" concept. The first indications are Creatine Transporter Deficiency syndrome, a disabling condition with no treatment affecting children and Amyotrophic Lateral Sclerosis.
The lead compound CBT101 demonstrated efficacy in a preclinical models models as well as a large cerebral and neuronal distribution in primate. The CMC reached noticeable milestones with several GMP batches produced.
Other mitochondriopathies are in the Ceres's pipeline.
CERES BRAIN Therapeutics has already raised up to 12M€ to move towards the clinical program.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Icm, Hôpital Pitié-Salpêtrière, Paris,france 75013,france
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.ceres-brain.com
- Keywords
- Representative jobs.
- HQ
- Paris, France
Ceres Brain Therapeutics Questions
Ceres Brain Therapeutics's website is https://www.ceres-brain.com
Ceres Brain Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/ceres-brain-therapeutics
Ceres Brain Therapeutics has
9 employees.
View email and phone details for 9
employees at Ceres Brain Therapeutics.
Ceres Brain Therapeutics's industry is
Pharmaceutical Manufacturing
Ceres Brain Therapeutics's top competitors are
Institut Du Cerveau – Paris Brain Institute,
Bluetheris,
Injectpower,
Eg 427,
Acticor Biotech,
Aken Medical,
Coave Therapeutics,
Kolibri,
En Carta Diagnostics,
Helios Neopharma.
Ceres Brain Therapeutics's categories are Pharmaceutical Manufacturing
Ceres Brain Therapeutics's founding year is 2019
